Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Glenmark and Ichnos Join Forces to Drive Innovation in Cancer Treatment through ‘Ichnos Glenmark Innovation’ Alliance

NextEdge Admin

31 Jan 2024

2 min 17 sec

Glenmark Pharmaceuticals Ltd. and its global biotech subsidiary, Ichnos Sciences Inc., have officially launched their collaborative effort, Ichnos Glenmark Innovation (IGI), aimed at expediting the discovery of new cancer treatments. This strategic alliance harnesses Glenmark’s expertise in small molecule research and development along with Ichnos’s proficiency in novel biologics to advance cutting-edge therapy solutions for hematological malignancies and solid tumors.

IGI boasts a robust pipeline of three innovative oncology molecules currently undergoing clinical trials, targeting multiple myeloma, acute myeloid leukemia, and solid tumors. Two of these molecules have received orphan drug designation from the U.S. FDA. Additionally, IGI possesses two autoimmune disease assets that have been licensed to leading companies.

With the collaborative efforts of over 150 scientists, IGI will capitalize on its three global centers of innovation. These include Ichnos’s headquarters in New York City, NY, USA, focused on clinical development; the biologics research center in Lausanne, Switzerland; and Glenmark’s small molecule research center in Mumbai, India.

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, expressed pride in the IGI alliance, highlighting its commitment to accelerating cancer research and developing novel drugs. Cyril Konto, President and CEO of Ichnos Glenmark Innovation, emphasized IGI’s collaborative nature, backed by a collective pipeline of multispecifics and small molecules. He expressed the intention to collaborate with other entities, including biotech companies and academia, to further enhance drug development and scientific advancements.